Malignant abdominal masses in children: Quick guide to evaluation an diagnosis

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1369-1392

  Golden, Carla B ^a   Feusner, James H ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HOMOVANILLIC ACID; IFOSFAMIDE; NEURON SPECIFIC ENOLASE; PREDNISONE; PROTEIN; TOPOTECAN; TUMOR MARKER; VANILMANDELIC ACID; VASCULOTROPIN ANTIBODY; VINCRISTINE; WT1 PROTEIN;

ABDOMINAL MASS; ABDOMINAL RADIOGRAPHY; ADRENAL CORTEX CARCINOMA; ANGIOSARCOMA; BEAM THERAPY; CANCER STAGING; CARCINOID; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; GERM CELL TUMOR; HEPATOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOMA; MULTIMODALITY CANCER THERAPY; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SARCOMA; STEM CELL TRANSPLANTATION; TERATOMA; THORAX RADIOGRAPHY;

ABDOMINAL NEOPLASMS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; INFANT; INFANT, NEWBORN; PRACTICE GUIDELINES;

EID: 0036974051     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00098-6     Document Type: Review

References (102)

1. Merten DF, Kirks DR. Diagnostic imaging of pediatric abdominal masses. Pediatr Clin North Am 1985;32:1397-425.
2. Matthay KK. Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin 1995;45:179-92.
3. Berthold F, Brandeis WE, Lampert F. Neuroblastoma: diagnostic advances and therapeutic results in 370 patients. Monogr Paediatr 1996;18:206-23.
4. Kinnier-Wilson LM, Draper GJ. Neuroblastoma, its natural history and prognosis: a study of 487 cases. BMJ 1974;3:301-7.
5. Turkel SB, Itabashi HH. The natural history of neuroblastomic cells in the fetal adrenal gland. Am J Pathol 1975;76:225-43.
6. Ikeda Y, Lister J, Bouton JM, et al. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J Pediatr Surg 1981;16:636-44.
7. Bessho F. Comparison of the incidences of neuroblastoma for screened and unscreened cohorts. Acta Paediatr 1999;88:404-6.
8. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996;348:1682-7.
9. Woods WG, Tuchman M, Robison LL, et al. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children. Eur J Cancer 1997;33:2106-12.
10. Kramer K, Kushner B, Heller G, et al. Neuroblastoma metastatic to the central nervous system. Cancer 2001;91:1510-9.
11. Kammen BF, Matthay KK, Pacharn P, et al. Pulmonary metastases at diagnosis of neuroblatoma in pediatric patients: CT findings and prognosis. Am J Roentgenol 2001;176:755-9.
12. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81.
13. Graham-Pole J, Salmi T, Anton AH, et al. Tumor and urine catecholamines (CATS) in neurogenic tumors. Correlations with other prognostic factors and survival. Cancer 1983;51:834-9.
14. LaBrosse EH, Com-Nougue C, Zucker JM, et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980;40:1995-2001.
15. Laug WE, Siegel SE, Shaw KNF, et al. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978;62:77-83.
16. Bourhis J, DeVathaire F, Wilson GD, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991;51:33-6.
17. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995;31A:505-10.
18. Brodeur GM, Ambros PF. Genetic and biological markers of prognosis in neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, et al, editors. Neuroblastoma. Amsterdam: Elsevier Science; 2000. p. 355-69.
19. Brodeur GM, Maris JM, Yamashiro DJ, et al. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997;19:93-101.
20. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 1992;14:111-6.
21. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
22. Katzenstein H, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a Pediatric Oncology Group study. J Clin Oncol 1998;16:2007-17.
23. Kawa K, Ohnuma N, Kaneko M, et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 1999;17:3216-20.
24. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc amplification in childhood neuroblastoma. A Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
25. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998;16:1256-64.
26. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine the prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol 2000; 18:1260-8.
27. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
28. Shimada H, Ambros IM, Dehner LP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
29. Fishman EK, Harman DS, Goldman SM, et al. The CT appearance of Wilms' tumor. J Comput Assist Tomogr 1983;7:659-65.
30. Caron H, Van Sluis P, De Kraker J, et al. Allelic loss of chromosome lp as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
31. Maris JM, Guo C, Blake D, et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 2001;36:32-6.
32. Brodeur GM, Pritchard J, Berthold F, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993;11:1466-77.
33. Strother DR, Shuster JJ, McWilliams N, et al. Results of a Pediatric Oncology Group protocol 8104 for infants with stages D and 4S neuroblastoma. J Pediatr Hematol Oncol 1995; 17:254-9.
34. Matthay KK, Lukens J, Haase G, et al. Outcome and prognostic factors for 1008 children with neuroblastoma treated from 1989-1995 on Children's Cancer Group (CCG) protocols. 6th Symposium on Advances in Neuroblastoma Research. Philadelphia, PA, May 13-15, 1993. Prog Clin Biol Res 1994;385:1-448.
35. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study. J Clin Oncol 1988;6:1271-9.
36. Evans AE, Silber JH, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996;14:2504-10.
37. Kushner BH, Cheung NK, LaQuaglia P, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996;14:373-81.
38. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989;7:236-44.
39. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol 2000;18:
40. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1997;15:1171-82.
41. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. Children's Cancer Gourp. New Engl J Med 1999;341:1165-73.
42. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 1999;81:1378-84.
43. Goldberg SS, DeSantes K, Huberry JP, et al. Engraftment after myeloablative doses of 131 I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol 1998;30:339-46.
44. Mastrangelo R, Tonesello A, Mastrangelo S. Role of 131 I-metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol 1998;31:22-6.
45. Matthay KK, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131 I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-36.
46. Sisson JC, Shapiro B, Hutchinson RJ, et al. Survival of patients with neuroblastoma treated with 125-I MIBG. Am J Clin Oncol 1996;19:144-8.
47. Tepmongkol S, Heyman S. 13 I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999;32:427-31.
48. Cheung IY, Lo Piccolo MS, Collins N, Kushner BH, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 2002;94:3024-8.
49. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside gd2 monoclonal antibody (chI4.18) with granulocyte-macrophage-colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Oncology Cancer Group study. J Clin Oncol 2000;18:4077-85.
50. Bowman LC, Grossman M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998;9:1303-11.
51. Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with antiganliodide GD2 antibody plus interleukin-2 induces antibody-dependent cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994;15:29-37.
52. Yoshida H, Enomoto H, Kawamura K, et al. Antitumor vaccine effect of irradiated murine neuroblastoma cells producing interleukin-2 or granulocyte macrophage-colony stimulating factor. Int J Oncol 1998;13:73-8.
53. Eggert A, Grotzer MA, Ikegaki N, et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 2001;19:689-96.
54. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, et al. Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 1999;5:4273-8.
55. Crist WM, Kun LE. Common solid tumors of childhood. N Engl J Med 1991;324:461-71.
56. Coppes MJ, deKraker J, van Digler PJ, et al. Bilateral Wilms' tumor: long term survival and some epidemiological features. J Clin Oncol 1989;7:310.
57. Breslow NE, Olson J, Moksness J. Familial Wilms' tumor: a descriptive study. Med Pediatr Oncol 1996;27:398-403.
58. Grundy P, Koufos A, Morgan K, et al. Familial predisposition to Wilms' tumor does not map to the short arm of chromosome 11. Nature 1988;336:374-6.
59. Clericuzio CL, Johnson C. Screening for Wilms' tumor in high-risk individuals. Hematol Oncol Clin N Am 1995;9:1253-65.
60. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
61. Koufos A, Grundy P, Morgan K, et al. Familial Wiedmann-Beckwith syndrome and a second Wilms' tumor locus both map to 11p15.5. Am J Hum Genet 1989;44:711-9.
62. Li M, Squire J, Weksberg R. Molecular genetics of Beckwith-Wiedemann syndrome. Curr Opin Pediatr 1997;9:623-9.
63. Ganguly A, Gribble J, Tune B, et al. Renin-secreting Wilms' tumor with severe hypertension: report of a case and brief review of renin-secreting tumors. Ann Intern Med 1973;79:835-7.
64. Coppes MJ, Zandvoort SWH, Sparling CR, et al. Acquired von Willebrand disease in Wilms' tumor patients. J Clin Oncol 1992;10:422-7.
65. Poerink-Stockschlader ABJ, Dekker I, Risseeuw-Appel IM, et al. Acquired Von Willebrand disease in children with a Wilms' tumor. Med Pediatr Oncol 1996;26:238-43.
66. Nakayama DK, Norkool P, deLorimier AA, et al. Intracardiac extension of Wilms' tumor. Ann Surg 1986;204(6):693-7.
67. Ritchey ML, Kelalis PP, Haase GM. Preoperative therapy for intracaval and atrial extension of Wilms' tumor. Cancer 1993;71:4104-10.
68. Breslow NE, Churchill G, Nesmith B, et al. Clinicopathologic features and prognosis for Wilms' tumor patients with metastases at diagnosis. Cancer 1986;58:2501-11.
69. Feusner JH, Beckwith JB, D'Angio GJ. Clear cell sarcoma of the kidney: accuracy of imaging methods for detecting bone metastases. Report from the National Wilms' Tumor Study. Med Pediatr Oncol 1990;18:225-7.
70. Gururangan S, Wilimas JA, Fletcher BD. Bone metastases in Wilms' tumor-report of three cases and review of literature. Pediatr Radiol 1994;24:85-7.
71. Bonnin JM, Rubinstein LJ, Palmer NF, et al. The association of embryonal tumors originating in the kidney and in the brain. A report of seven cases. Cancer 1984;54:2137-46.
72. Palmer NF, Surrow WW. Clinical aspects of the rhabdoid tumor of the kidney: a report of the National Wilms' Tumor Study Group. Med Pediatr Oncol 1983;11:242-5.
73. Weeks DA, Beckwith JB, Mierau GW, et al. Rhabdoid tumor of kidney: a report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 1989;13:439-58.
74. Ritchey ML, Green M, Thomas PRM, et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996;26:75-80.
75. Green DM, D'Angio GL, Beckwith JB, et al. Wilms' tumor. CA Cancer J Clin 1996;46:46-63.
76. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:3744-51.
77. Dome JS, Tiebin L, Krasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hemayol Oncol 2002;24:192-8.
78. Abu-Ghosh AM, Krailo M, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol 2002;13:460-9.
79. Pein F, Tournade M, Zucker J, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor - a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994;12:931-6.
80. Dagher R, Kreissman S, Robertson KA, et al. High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor. J Pediatr Hematol Oncol 1998;20:357-60.
81. Garaventa A, Hartmann O, Bernard J, et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994;22:11-4.
82. Blann AD, Li JL, Kumar S. Increased serum VEGF in 13 children with Wilms' tumour falls after surgery but rising levels predict poor prognosis., Cancer Lett 2001;173:183-6.
83. Soffer SZ, Moore JT, Kim E, et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms' tumor. J Pediatr Surg 2001;36:1177-81.
84. Kingston JE, Herbert A, Draper GJ, et al. Association between hepatoblastoma and polyposis coli. Arch Dis Child 1983;58:959-62.
85. Li FP, Thurber WA, Seddon J, et al. Hepatoblastoma in families with polyposis coli. JAMA 1987;257:2475-7.
86. Feusner JH, Ortega J, Haas J, Quinn J, King A, Ablin A, et al. Hepatoblastoma in premature infants. Proceedings of the American Society of Clinical Oncology 1997;16:525a.
87. Ikeda H, Hachitanda Y, Tanimura M, et al. Development of unfavorable hepatoblastoma in children of very low birth weight. Cancer 1998;82:1789-96.
88. Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: a trend or a chance. J Pedatrics 1997;130:557-60.
89. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. J Clin Oncol 1997;15:1190-7.
90. Feusner JH, Krailo M, Haas J, et al. Treatment of pulmonary metastases in initial stage I hepatoblastoma of childhood. Cancer 1993;71:859-64.
91. Douglass EC, Reynolds M, Finegold M, et al. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol 1993;11:96-9.
92. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000;18:2665-75.
93. Malogolowkin MH, Stanley P, Steele D, et al. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 2000;18:1279-84.
94. Hass J, Feusner J, Finegold M. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 2001;92:3130-4.
95. Eriksson T, Frisk T, Gray SG, et al. Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma. Exp Cell Res 2001;270:88-95.
96. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21(27):4345-9.
97. Link M, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997;337:1259-66.
98. Patte C, Auperin A, Michon J, et al. The Societe Francais d'Oncologie Peadiatrique LMP89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial reponse in 561 unselected children with B cell lymphomas and L3 leukemia. Blood 2001;97:3370-9.
99. Gobel U, Calaminus G, Schneider DT, et al. Management of germ cell tumors in children: approaches to cure. Onkologie 2002;25:14-22.
100. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999;94:3294-306.
101. Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Children's Cancer Group Intergroup study. J Clin Oncol 1999;17:2137-43.
102. Bulterys M, Goodman MT, Smith MA, Buckley JD. Hepatic tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999 [Chapter 7].